Pharmametics(Stem Cell Factor–PLLA Conjugation): Manufacturing Process and Clinical Efficacy for Plastic Surgery Applications

Cover Letter

To the Editor,

Plastic and Reconstructive Surgery (or target journal name)

Dear Editor,

We are pleased to submit our manuscript entitled “Pharmametics (Stem Cell Factor–PLLA Conjugation): Manufacturing Process and Clinical Efficacy for Plastic Surgery Applications.”

This study introduces a novel biomaterial platform combining Stem Cell Factors with Poly(L)‑Lactide (PLLA) through a controlled conjugation process.

The workflow ensures stable covalent bonding and sustained release of regenerative proteins.

Clinical evaluation demonstrated 100 % cell viability, 53 % reduction in MMP‑1 expression, and 16 % increase in procollagen synthesis, confirming both safety and regenerative efficacy.

The findings provide a foundation for next‑generation regenerative biomaterials applicable to facial rejuvenation, scar revision, and tissue reconstruction in plastic surgery.

We believe this manuscript will be of interest to your readership because it bridges stem cell biotechnology and clinical plastic surgery, offering a reproducible and biocompatible platform for regenerative treatment.

All authors have approved the manuscript and declare no conflicts of interest.

This work was conducted at Kyung Hee University Skin Biotechnology Center in collaboration with Natural Science Inc[SSMR].

Thank you for considering our submission.

Sincerely,

Kihwong. Zheng, Ph.D.

SSMR (Natural Science Inc.)

Email: [pharmametics@gmail.com]

Phone: +82-10-3449-7249

---

Title

Pharmametics(Stem Cell Factor–PLLA Conjugation): Manufacturing Process and Clinical Efficacy for Plastic Surgery Applications

---

Abstract

This study introduces a biomaterial platform combining Stem Cell Factors with Poly(L)‑Lactide (PLLA) through a controlled conjugation process. The workflow—stem cell culturing, factor isolation, PLLA synthesis, and conjugation—ensures stable covalent bonding and sustained release of regenerative proteins. Clinical evaluation demonstrated 100 % cell viability, 53 % reduction in MMP‑1 expression, and 16 % increase in procollagen synthesis. These findings confirm both safety and regenerative efficacy, supporting applications in plastic surgery for facial rejuvenation, scar revision, and tissue reconstruction.

---

1. Introduction

Plastic surgery increasingly integrates regenerative medicine to enhance healing and aesthetic outcomes. Stem cell factors—growth factors, cytokines, and exosomes—stimulate fibroblast activity and collagen synthesis. PLLA, a biodegradable polymer, provides a scaffold for controlled release. The Stem Cell Factor–PLLA Conjugation process merges these advantages, offering a next‑generation injectable or implantable biomaterial for anti‑aging and reconstructive procedures. This name is Pharmametics.

---

2. Materials and Methods

2.1 Manufacturing Workflow

Fig 1. Manufacturing Workflow

Stem Cell Culturing → Factor Isolation → PLLA Synthesis → Conjugation.

Workflow of Stem Cell Factor–PLLA Conjugation showing stepwise production and bonding.

2.2 Clinical Evaluation

Fig 2. Clinical Efficacy Results

• MMP‑1 Reduction: −53 %

• Procollagen Increase: +16 %

• Cell Viability: 100 %

Comparative efficacy normalized to 100 % baseline.

---

3. Results

Fig 3. Clinical Data Summary

Parameter Baseline Post‑Treatment Change Interpretation

Cell Viability 100 % 100 % 0 % Non‑toxic

MMP‑1 Expression 100 % 47 % −53 % Collagen degradation inhibited

Procollagen Synthesis 100 % 116 % +16 % Collagen formation enhanced

---

4. Discussion

Fig 4. Mechanism of Action

Released stem cell factors from PLLA conjugates activate fibroblasts, inhibit MMP‑1, and stimulate collagen synthesis.

Sustained release leads to reduced collagen breakdown and enhanced dermal regeneration.

---

5. Conclusion

The Pharmametics (Stem Cell Factor–PLLA Conjugation) system demonstrated robust manufacturing and clinical efficacy, supporting advancement into plastic surgery trials for facial rejuvenation, scar revision, and reconstructive applications.

---

Acknowledgments

Conducted at Kyung Hee University Skin Biotechnology Center in collaboration with Natural Science Co., Ltd.

---

References

1. Wang Y et al. Lyophilization and Protein Stability in Biopharmaceuticals. J Pharm Sci, 2022.

2. Smith J & Chen L. Poly‑L‑Lactic Acid Conjugation Strategies for Controlled Release. Biomaterials, 2021.

3. Patel R et al. Stem Cell Factors in Regenerative Medicine. Regenerative Biology, 2024.

---